Nascent Successfully Completes 2nd Cohort Dosing in Key Phase 1 Metastatic Brain Cancer Trial

Rhea-AI Summary

Nascent Biotech (OTCQB:NBIO) has completed dosing for the second cohort in its Phase I trial evaluating Pritumumab (PTB) as a treatment for brain cancer. This achievement allows the company to advance to its third cohort, anticipated to commence shortly. PTB is a targeted immunotherapy designed to specifically attack cancer cells without harming healthy cells. Positive data trends have been reported, paving the way for a future petition for Phase 2 testing. The company continues to push forward in its mission to develop innovative cancer treatments.

Positive

• Completed dosing of the second cohort in the Phase I trial for Pritumumab.
• Positive data trends observed during the trial.
• Anticipation of starting the third cohort soon.
• Potential to petition for Phase 2 testing following successful results.

Negative

• None.

VERO BEACH, FL / ACCESSWIRE / January 11, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce the completion of dosing of the second cohort of patients involved in the Company's Phase I trial to evaluate Pritumumab ("PTB") as a treatment for Brain Cancer, including Malignant Primary Brain Tumors and adult Brain Metastases.

"After reviewing data gathered from the first and second cohorts, this milestone will allow us to quickly advance to our third cohort in the study, which is anticipated to start this month," noted Nascent CEO, Sean Carrick.

PTB is a natural human antibody that works by binding to Cell surface Vimentin (also referred to as ectodomain vimentin, or EDV), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy that, unlike chemotherapy, only targets cancer cells without damaging healthy cells.

Carrick continued, "Having successfully completed the first two cohorts associated with this important trial, we are excited to move to our third escalation. Our rapid progress to this stage, and the positive data trends we have seen in the course of that process, moves us closer to petitioning for approval to begin Phase 2 testing."

Those interested in participating in the trial or finding out more information are invited to visit www.clinicaltrials.gov under the search term "Pritumumab".

About Nascent Biotech

Nascent Biotech, Inc. (OTCQB:NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers and viral infections, helping people worldwide. Its products are not yet commercially available. The Company's lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) that is being studied in Phase I clinical trials for the treatment of Brain Cancer.

For further information please visit our website www.nascentbiotech.com.

Forward Looking Safe Harbor Statement

Statements in this press release about our future expectations constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc's Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Corporate Contact

Sean Carrick | President | CEO | Nascent Biotech, Inc.
772.713.0541 Cell | sean.carrick@nascentbiotech.com

Public Relations

EDM Media, LLC
https://edm.media
(800) 301-7883

SOURCE: Nascent Biotech Inc.

View source version on accesswire.com:
https://www.accesswire.com/681450/Nascent-Successfully-Completes-2nd-Cohort-Dosing-in-Key-Phase-1-Metastatic-Brain-Cancer-Trial

FAQ

What is the current phase of the Pritumumab trial for brain cancer?

The trial is currently in Phase I, with the second cohort completed and the third cohort expected to start shortly.

What are the implications of the second cohort completion for Nascent Biotech?

Completing the second cohort allows Nascent Biotech to advance to further testing and potentially accelerate the path to Phase 2.

What type of cancer is being targeted by Pritumumab?

Pritumumab is being studied for the treatment of brain cancer, including malignant primary brain tumors and adult brain metastases.

Is Pritumumab a chemotherapy treatment?

No, Pritumumab is a targeted immunotherapy that specifically targets cancer cells without affecting healthy cells.